Table II.
Clinicopathological characteristics according to PT and LN responses to NAC.
| Primary tumor | Lymph node | |||||
|---|---|---|---|---|---|---|
|
|
|
|||||
| Factors | Res (n=6) | Non-res (n=8) | P-value | Res (n=8) | Non-res (n=6) | P-value |
| Age | 0.33 | |||||
| ≥70 years | 3 | 2 | 2 | 3 | ||
| <70 years | 3 | 6 | 0.33 | 6 | 3 | |
| Sex | 0.35 | |||||
| Male | 6 | 5 | 7 | 4 | ||
| Female | 0 | 3 | 0.10 | 1 | 2 | |
| Tumor location | 0.12 | |||||
| Upper/Middle | 5 | 3 | 6 | 2 | ||
| Lower | 1 | 5 | 0.09 | 2 | 4 | |
| Tumor size | 0.12 | |||||
| ≥50 mm | 2 | 5 | 2 | 4 | ||
| <50 mm | 4 | 3 | 0.28 | 6 | 2 | |
| Differentiation | 0.08 | |||||
| Well/Moderate | 1 | 2 | 2 | 1 | ||
| Poor | 4 | 3 | 5 | 2 | ||
| Others | 1 | 3 | 0.54 | 1 | 3 | |
| cT stage | 0.53 | |||||
| T1-3 | 3 | 3 | 4 | 2 | ||
| T4 | 3 | 5 | 0.64 | 4 | 4 | |
| cN stage | 0.28 | |||||
| N1 | 2 | 5 | 3 | 4 | ||
| T2-3 | 4 | 3 | 0.28 | 5 | 2 | |
| Surgical procedure | 0.33 | |||||
| DG | 2 | 3 | 2 | 3 | ||
| TG | 4 | 5 | 0.87 | 6 | 3 | |
| NAC regimen | 0.87 | |||||
| DCS | 4 | 5 | 5 | 4 | ||
| SOX | 2 | 3 | 0.87 | 3 | 2 | |
| Histological grade | 0.12 | |||||
| 0, 1 | 2 | 4 | 2 | 4 | ||
| 2, 3 | 4 | 4 | 0.53 | 6 | 2 | |
| LCR | 0.53 | |||||
| High | 4 | 2 | 4 | 4 | ||
| Low | 2 | 6 | 0.12 | 4 | 2 | |
| NLR | 0.35 | |||||
| High | 5 | 2 | 7 | 2 | ||
| Low | 1 | 6 | 0.71 | 1 | 4 | |
| PNI | 0.20 | |||||
| High | 5 | 4 | 4 | 1 | ||
| Low | 1 | 4 | 0.20 | 4 | 5 | |
DCS, docetaxel + cisplatin + S-1; DG, distal gastrectomy; LCR, lymphocyte-C-reactive protein ratio; LN, lymph node; NAC, neoadjuvant chemotherapy; NLR, neutrophil-lymphocyte ratio; Non-res, nonresponse; PNI, prognostic nutritional index; PT, primary tumor site; Res, response; SOX, S-1 + oxaliplatin; TG, total gastrectomy.